TUL ranked 22nd in the "2021 Top 100 Enterprises in China's Pharmaceutical Industry"

On December 18, 2022, the 39th National Pharmaceutical Industry Information Annual Conference was grandly held in Shanghai, and the "2021 Top 100 List of China's Pharmaceutical Industry" was officially released. Zhuhai United Laboratories Co., Ltd. ranked 22nd in the Top 100 list. In 2021, the pharmaceutical industry achieved restorative growth in a severe environment, with revenue exceeding one trillion yuan for the first time. In 2021, the overall revenue of China's top 100 pharmaceutical industry enterprises was 1076.2 billion yuan, a year-on-year increase of 19.4%. The threshold for top 100 enterprises to be listed has increased from 2.78 billion yuan to 3.14 billion yuan, a year-on-year increase of 12.9%. Adhering to the enterprise tenet of "making life more valuable", TUL complies with the development and reform of China's pharmaceutical and health industry, consolidates the development of core business, actively promotes scientific research and innovation, and constantly introduces new drugs. In the formulation product TUL ® Amoxian ® (Amoxicillin Capsules), Yousilin USLIN ® (Human insulin for injection series products), the intermediate penicillin G potassium industrial salt, bulk drug semi synthetic penicillin and other series of brand products led by TUL's revenue of 9.703 billion yuan in 2021, an increase of 10.6% year on year. TUL will continue to increase its R&D and innovation efforts, improve the level of industrial manufacturing, enhance the supply guarantee ability of various drugs, improve the core competitiveness of enterprises, and make contributions to the development of China's pharmaceutical industry and the cause of people's health.